These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 8729588

  • 21. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group.
    Jacotot B, Banga JD, Waite R, Peters TK.
    Am J Cardiol; 1995 Jul 13; 76(2):41A-46A. PubMed ID: 7604796
    [Abstract] [Full Text] [Related]

  • 22. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 13; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 23. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 13; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 24. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S, Pogarell O, Keller C, Wolfram G.
    Arzneimittelforschung; 1996 Sep 13; 46(9):879-83. PubMed ID: 8876936
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD.
    Am J Cardiol; 1995 Jul 13; 76(2):37A-40A. PubMed ID: 7604795
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, Knopp R, McKenney J, Stein E, Troendle AJ.
    Arch Intern Med; 1994 Nov 14; 154(21):2449-55. PubMed ID: 7979841
    [Abstract] [Full Text] [Related]

  • 27. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR.
    Arch Intern Med; 1990 Feb 14; 150(2):341-5. PubMed ID: 2405804
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy.
    Jacobson TA, Jokubaitis LA, Amorosa LF.
    Am J Med; 1994 Jun 06; 96(6A):64S-68S. PubMed ID: 8017469
    [Abstract] [Full Text] [Related]

  • 30. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM, Katyal A.
    Mo Med; 2002 Jun 06; 99(10):580-4. PubMed ID: 12534147
    [Abstract] [Full Text] [Related]

  • 31. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H, Beil FU, Schneider J, Weisweiler P, Armstrong VW, Keller C, Klör HU, von Hodenberg E, Weidinger G, Eskötter H.
    Am J Med; 1994 Jun 06; 96(6A):55S-63S. PubMed ID: 8017468
    [Abstract] [Full Text] [Related]

  • 32. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
    Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L.
    Ann Intern Med; 1994 Apr 01; 120(7):537-43. PubMed ID: 8093139
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine.
    Hagen E, Istad H, Ose L, Bodd E, Eriksen HM, Selvig V, Bard JM, Fruchart JC, Borge M, Wolf MC.
    Eur J Clin Pharmacol; 1994 Apr 01; 46(5):445-9. PubMed ID: 7957541
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B, Ezetimibe Study Group.
    Clin Ther; 2005 Feb 01; 27(2):174-84. PubMed ID: 15811480
    [Abstract] [Full Text] [Related]

  • 37. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M, Sailer S, Irsigler H, Klein W, Patsch JR.
    Wien Med Wochenschr; 1995 Feb 01; 145(21):577-83. PubMed ID: 8560901
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
    Jacobson TA, Amorosa LF.
    Am J Cardiol; 1994 May 26; 73(14):25D-29D. PubMed ID: 8198020
    [Abstract] [Full Text] [Related]

  • 40. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH, Donovan JM, Misir S, Jones MR.
    Am J Cardiovasc Drugs; 2010 May 26; 10(5):305-14. PubMed ID: 20860413
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.